Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02147990
Title TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Clovis Oncology, Inc.
Indications

lung non-small cell carcinoma

Therapies

Rociletinib

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | DEU | CAN


No variant requirements are available.